braun tall getty

Report: Alex Rodriguez, Ryan Braun among players MLB seeks to suspend for Biogensis connection

124 Comments

Performance-enhancing drugs loomed large entering the baseball season, amid reports that dozens of players — many of them high-profile stars — could be suspended because of their reported involvement with a clinic that supplied PEDs.

That story just got bigger.

From ESPN.com investigative reporters T.J. Quinn, Pedro Gomez and Mike Fish:

Major League Baseball will seek to suspend about 20 players connected to the Miami-area clinic at the heart of an ongoing performance-enhancing drug scandal, including Alex Rodriguez and Ryan Braun, possibly within the next few weeks, “Outside the Lines” has learned. If the suspensions are upheld, the performance-enhancing drug scandal would be the largest in American sports history.

Tony Bosch, the former director of the Miami-based Biogenesis clinic, is “expected to begin meeting with officials — and naming names — within a week,” according to the ESPN.com report. A source familiar with the case confirmed to The Associated Press early Wednesday morning that Bosch has indeed agreed to talk to MLB about players linked to PEDs, and that Bosch’s information could lead to suspensions. The suspensions could be issued within two weeks, though there’s likely to be an appeals process and that may take a few months.

NBCSports.com reached both Major League Baseball and the Players’ Association on Tuesday night, but both declined to comment. Terry Fahn, Rodriguez’s publicist as of January, said to contact New York publicist Ron Berkowitz; Berkowitz declined to comment when reached by phone.

MORE: A closer look at the players facing potential suspensions

The commissioner’s office will be seeking 100-game punishments for Braun and A-Rod because they both committed two offenses — the initial doping and then lying to Major League Baseball officials. The typical punishment for first-time performance-enhancing drug offenders is a 50-game suspension.

Nationals left-hander Gio Gonzalez is not a candidate for suspension, according to Quinn, because Bosch is expected to confirm to the investigators that Gio only bought league-approved substances. Some of the other names that were found in the Biogenesis documents: Melky Cabrera, Bartolo Colon, Yasmani Grandal, Nelson Cruz, Francisco Cervelli, Jesus Montero, Jhonny Peralta, Cesar Puello, Fernando Martinez, Everth Cabrera, Fautino de los Santos and Jordan Norberto.

MORE: Why a mass suspension would be a mass fail

The Biogenesis news broke in late January, when it was reported by multiple outlets that Major League Baseball was investigating Bosch under the suspicion that his clinic represented “ground zero” for performance enhancing drugs in Florida, where a disproportionate number of major leaguers grew up, played amateur and college baseball or where they currently make their offseason homes. On January 29, the Miami New Times obtained and published a large portion of the Biogenesis clinic’s records which contained the names of several major leaguers accompanied in many cases by notations which suggested that the players were given performance enhancing drugs. The documents were not conclusive of any player’s use and, in some cases — like with Gio Gonzalez — no connection could be found between the player and any substances which are banned by Major League Baseball.

Immediately after the Miami New Times report came out all of the players involved either denied any involvement with Biogenesis whatsoever or denied that they obtained banned substances.  For example, Gonzalez claims that his father was a patient of Bosch’s. Ryan Braun claims that his attorneys used Bosch as a consultant in his successful 2012 appeal of his PED suspension. Despite the denials, the report and the documents set off a media firestorm which caused Major League Baseball to step up its investigation of the players named therein.

Danny Espinosa reportedly skipped Nationals Winterfest because of Adam Eaton

WASHINGTON, DC - OCTOBER 13: Danny Espinosa #8 of the Washington Nationals celebrates after teammate Chris Heisey #14 (not pictured) hits a two run home run in the seventh inning against the Los Angeles Dodgers during game five of the National League Division Series at Nationals Park on October 13, 2016 in Washington, DC. (Photo by Rob Carr/Getty Images)
Getty Images
8 Comments

According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.

A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.

Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.

Espinosa will reach free agency after the 2017 season.

Nick Cafardo: Red Sox should deal Pomeranz, not Buchholz

BOSTON, MA - SEPTEMBER 18: Drew Pomeranz #31 of the Boston Red Sox pitches during the first inning against the New York Yankees at Fenway Park on September 18, 2016 in Boston, Massachusetts. The Red Sox won 5-4. (Photo by Rich Gagnon/Getty Images)
Getty Images
11 Comments

The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.

The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.

Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.

Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.